Detalhe da pesquisa
1.
International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
BJU Int
; 133(2): 179-187, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37463104
2.
A four-group urine risk classifier for predicting outcomes in patients with prostate cancer.
BJU Int
; 124(4): 609-620, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31106513
3.
Multi-candidate immunohistochemical markers to assess radiation response and prognosis in prostate cancer: results from the CHHiP trial of radiotherapy fractionation.
EBioMedicine
; 88: 104436, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36708693
4.
Methodology for tissue sample collection within a translational sub-study of the CHHiP trial (CRUK/06/016), a large randomised phase III trial in localised prostate cancer.
Clin Transl Radiat Oncol
; 10: 1-6, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-29928699
5.
Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer.
Int J Radiat Oncol Biol Phys
; 101(2): 309-315, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29559283